We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics


Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App

Beckman Coulter and Fujirebio Partner to Widen Access to Blood-Based Alzheimer's Test

By LabMedica International staff writers
Posted on 18 Jul 2023
Print article
Image: The partnership will addresses the global unmet clinical need for blood-based Alzheimer`s Disease diagnostics (Photo courtesy of Fujirebio)
Image: The partnership will addresses the global unmet clinical need for blood-based Alzheimer`s Disease diagnostics (Photo courtesy of Fujirebio)

The increasing rate of disability and mortality due to neurological disorders is gradually being recognized as a significant global health issue, with the impact set to escalate in the forthcoming decades. Currently, Alzheimer's Disease International estimates that over 55 million people globally live with dementia, a figure projected to escalate to 139 million by 2050. With over 100 disease-altering drugs in the development pipeline, the potential for new therapeutics is greater than ever. The recent FDA approval of two monoclonal antibody-based treatments marks a significant breakthrough in improving Alzheimer's patients' health and slowing disease progression. Now, two companies are partnering to leverage their respective strengths in immunoassay to support the development of therapeutics, clinical trials, reimbursement, and standard clinical adoption in the field of neurodegenerative diseases.

Beckman Coulter, Inc. (Brea, CA, USA) and Fujirebio (Tokyo, Japan) have established a partnership that will capitalize on Fujirebio's skill in developing its pioneering, high-quality neurodegenerative disease biomarker assays and generating clinical evidence to boost clinical adoption. Beckman Coulter contributes its proprietary high-sensitivity detection capabilities and a wide base of immunoassay analyzers to facilitate global availability and support for the development of more accurate next-generation solutions. Fujirebio and Beckman Coulter aim to enhance access to patient-friendly, blood-based diagnostic capabilities to supplement and speed up the impact of pioneering Alzheimer's Disease therapeutics, complementing the current diagnostic solutions relying on PET-imaging or lumbar puncture for cerebral spinal fluid testing.

The growing prevalence of neurodegenerative diseases, coupled with advancements in disease-modifying therapies for Alzheimer's Disease, underscores the importance of the Beckman Coulter and Fujirebio partnership. This collaboration addresses the global need for blood-based Alzheimer's Disease diagnostics by expanding the menu on Beckman Coulter's Access Family of Immunoassay Analyzers, utilizing Fujirebio's assay technology. Initial assay development efforts will be focused on the recently introduced DxI 9000 Access Immunoassay Analyzer and the extensive installed base of Access Family Immunoassay Analyzers. The DxI 9000 Analyzer has demonstrated its potential to develop increasingly sensitive and clinically relevant assays, enabling the platform to keep up with the evolving testing needs as healthcare providers and pharmaceutical companies tackle challenging diseases, like Alzheimer's Disease.

Fujirebio holds the distinction of being the first company to gain FDA authorization for an in vitro diagnostic (IVD) test to evaluate β-amyloid pathology in patients' cerebral spinal fluid (CSF) being examined for Alzheimer's Disease. The company has developed a comprehensive array of blood-based neurodegenerative biomarkers for research use only (RUO), including β-amyloid1-42, β-amyloid1-40, phospho-Tau181, neurofilament light (NfL), ApoE4, and Pan-ApoE. By acquiring ADx NeuroSciences in June 2022, Fujirebio has added more biomarkers to its arsenal, broadening its portfolio. These new biomarkers offer clinical researchers the opportunity to delve deeper into the clinical relevance of evaluating Alzheimer's Disease or other neurological disorders. Fujirebio is set to validate the clinical efficacy of these blood-based neurodegenerative biomarkers, intending to shepherd them through the IVD regulatory procedures in the U.S., Europe, and Japan, leveraging Beckman Coulter's extensive installed base of analyzers for swift development.

"Combining the strengths of Fujirebio, the worldwide leader for neurodegenerative biomarker discovery and immunoassay development, with the global reach and high-sensitivity capabilities of Beckman Coulter's immunoassay installed base means patients, neurologists and general medical practitioners will have unmatched accessibility to high-quality neurodegenerative assays the world over. We at Beckman Coulter Diagnostics believe access to blood-based tests is critical to Alzheimer's Disease care," said Julie Sawyer Montgomery, President, Beckman Coulter Diagnostics and Danaher Diagnostics Group Executive.

"This collaboration with Beckman Coulter will help accelerate the deployment of our portfolio of new, novel neurodegenerative biomarkers to laboratories and clinicians around the world. As the pre-eminent provider of leading-edge immunoassays to the diagnostics industry, this partnership is an important step to speed the transition of these markers from research to clinical use in all major geographies and to bring a higher standard of care to patients and their families in the battle against this debilitating disease," added Goki Ishikawa, President & CEO, Fujirebio Holdings, Inc.

Related Links:
Beckman Coulter, Inc.

Platinum Supplier
Xylazine Immunoassay Test
Xylazine ELISA
Gold Supplier
PCR Microplate
Pregnancy Test
Concentrated Anionic Detergent

Print article


Clinical Chemistry

view channel
Image: The new assays are designed to run on the B•R•A•H•M•S KRYPTOR compact PLUS clinical chemistry analyzer (Photo courtesy of Thermo Fisher)

Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia

Preeclampsia is a life-threatening blood pressure condition that can arise during pregnancy and the postpartum phase. This severe pregnancy complication is a primary cause of maternal and fetal mortality... Read more

Molecular Diagnostics

view channel
Image: A CRISPR technology-based diagnostic test detects MPXV in clinical samples with acute precision (Photo courtesy of 123RF)

Powerful Diagnostic Tool Accurately Detects Monkeypox Virus Faster Than Any Method

At present, testing for the monkeypox virus (MPXV) is done mainly in centralized labs, and it can take days to get results due to location and logistical issues. Now, researchers have leveraged cutting-edge... Read more


view channel
Image: The US FDA has cleared HemoScreen point of care CBC for direct capillary sampling (Photo courtesy of PixCell Medical)

Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput

The world’s only 5-part differential Complete Blood Count (CBC) analyzer that is FDA-cleared, CE-marked, and TGA-approved for point-of-care use has now been granted FDA 510(k) clearance for direct capillary... Read more


view channel
Image: Immune cells present long before infection predict flu symptoms (Photo courtesy of Shutterstock.com)

Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms

For decades, if not centuries, scientists have struggled to solve the mystery of why certain individuals fall ill to infections while others remain unaffected. In an impressive development, researchers... Read more


view channel
Image: The rapid diagnostic test could pinpoint the correct antibiotic for infection treatment in under an hour (Photo courtesy of Microplate Dx)

Point-of-Care Device to Reduce Antibiotic Susceptibility Testing Time from Days to Minutes

Antimicrobial resistance (AMR) is a significant global health issue, currently leading to over 1.27 million deaths worldwide each year. By 2050, AMR could be causing up to 10 million deaths annually, surpassing... Read more


view channel
Image: The Tasso+ device has received CE Mark certification (Photo courtesy of Tasso)

Groundbreaking Blood Lancing Device Obtains Microliter Capillary Whole Blood Samples Painlessly

A convenient, virtually pain-free blood lancet that collects whole liquid blood samples has received CE Mark designation, making the patient-centric, high-volume blood collection solution available in... Read more


view channel
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.